Acasti pharma discusses positive clinical study results for gtx-101 and gtx-102 and upcoming phase 3 study for gtx-104 with the stock day podcast

Phoenix, arizona--(newsfile corp. - january 17, 2023) - the stock day podcast welcomed acasti pharma, inc. (nasdaq: acst), a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. ceo of the company, jan d'alvise, joined stock day host everett jolly. jolly began the interview by asking about the company's background and current projects.
ACST Ratings Summary
ACST Quant Ranking